Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Biktarvy in African American Adults with HIV-1
NCT03631732Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24. Started Aug 2018; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03631732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631732.